Asia Executives On The Move: Sanofi, GSK, Merck
The coming of spring has brought with it a plethora of pharma executives changes in the Asia Pacific. Sanofi has a new China GM, Merck China R&D head leaves for a startup and Daiichi Sankyo has a new head for its generics business.
You may also be interested in...
China's latest national census data paint a mixed picture for the provision of health in the world’s most populous nation, with multiple major trends potentially impacting areas of opportunity.
Authorities in China appear to be taking a tough early stance in the enforcement of a new national Biosecurity Law that took effect in mid-April, with an imported human cell shipment in Shanghai being seized.
US-based, China-focused CANbridge moves into cholestatic liver disease and enzyme replacement therapy via two deals. Plus deals involving LegoChem, TransThera, Morepen, Daiichi Sankyo, Geneseeq, Innocare, Biosplice, Sirnaomics and Walvax.